The Steering Committee solicits and reviews abstract submissions in specific topic areas for the annual conference in concert with the Scientific Committee. Each member of
the
Steering Committee is the chair of a topic-specific Scientific Committee sub-group.
The Educational Committee is independent of all other committees and is responsible for recruiting, reviewing and approving educational components that focus on the application of techniques rather than active research.
These components include short courses, academic workshops, and other practical training formats and content. The committee is composed of the Practical Training representatives that are serving on the Steering and Scientific Committees.
Tim Garrett, PhD University of Florida College of Medicine
Dr. Garrett has over 20 years of experience in the field of mass spectrometry spanning both instrument and application development. He received his PhD from the University of Florida, under Dr. Richard A. Yost, working on the first imaging mass spectrometry-based ion trap instrument. He has also developed MALDI-based approaches to analyze proteins in bacteria and small molecules in tissue specimens. His current interests include development of techniques and instrumentation for metabolomics science using LC-HRMS and translational work in diagnostics for dried blood spots. He is an Associate Professor in the Department of Pathology at the University of Florida, and Director for the Southeast Center for Integrated Metabolomics (SECIM).
Relevant Financial Disclosures
(within past 24 months, reported on Sep 11, 2025)
No relevant financial relationship(s) to disclose.
Outgoing Chair
Margret Thorsteinsdottir, PhD University of Iceland
Professor in Pharmaceutical Analytical Chemistry at the Faculty of Pharmaceutical Sciences, University of Iceland and R&D Director of ArcticMass LTd, Reykjavik, Iceland. Dr. Thorsteinsdóttir received her PhD from Uppsala University, Sweden in 1998. From 2000 to 2009 she was the managing director of Bioanalytical Laboratories at deCODE Genetics, Reykjavik, Iceland. She has extensive experience in development of analytical methods for metabolite profiling and quantification of clinical biomarkers in various biofluids utilizing chemometrics with the goal of improved clinical management of patients towards personalized patient care.
Her current research interest includes studies of lipid metabolism in cancer cells and profiling plasma derived biomarkers for early detection of BRCA-related breast cancer. She is responsible for implementation of clinical mass spectrometry for support of diagnostics and therapeutic drug monitoring in collaboration with ArcticMass and the Landspitali University Hospital, Reykjavik, Iceland with major focus on quantitative targeted proteomics for clinical diagnosis. She is a principal investigator of the Icelandic Research Rannis projects, profiling metabolites for breast cancer diagnosis and search for novel biomarkers for early breast cancer diagnosis by metabolomics. Dr. Thorsteinsdóttir is a principal investigator for the Marine Biotechnology ERA-net project CYNOBESITY and the Horizon 2020 project MossTech, with the main task to isolate, identify and structurally characterize bioactive compounds from cyanobacteria, Icelandic mosses and liverworts. She is one of the founders of Females in Mass Spectrometry (FeMS), she is a vice-leader of the working group clinical significance and applications of (epi)lipidomics in the pan-European network, EpiLipidNET and vice-chair of the Nordic Metabolomics Society.
Relevant Financial Disclosures
(within past 24 months, reported on Mar 12, 2025)
No relevant financial relationship(s) to disclose.
Steering Committee
Renee Ruhaak, PhD LUMC
Covering the topic area of (Glyco)Proteomics
Renee Ruhaak holds a PhD from the Leiden University Medical Center (LUMC, supervisor Prof. M. Wuhrer) and did a post-doc at UC Davis in the lab of Prof. C.B. Lebrilla prior to joining the department of Clinical Chemistry and Laboratory Medicine at the LUMC. She is currently an associate professor with a research focus on the application of mass spectrometry within the clinical setting. This entails both development and implementation of quantitative protein mass spectrometry, as well as the role of mass spectrometry in metrology and test standardization.
Relevant Financial Disclosures
(within past 24 months, reported on Feb 27, 2026)
Grant/Research Support
Octapharma
Daniel Holmes, MD, FRCPC St. Paul’s Hospital
Covering the topic area of Data Science
Daniel Holmes did his undergraduate training in Chemistry and Physics at the University of Toronto before deciding to pursue medicine as a career. He attended medical school at the University of British Columbia where pathology became his area of major interest. The strong influence of his academic mentors led him to enter the Medical Biochemistry residency training program at UBC. This allowed him to use his background knowledge of chemistry in application to medicine. Areas of clinical interest are diagnostic lipidology/endocrinology and research interests are in the utilization of mathematics and computer diagnostics to laboratory medicine.
Relevant Financial Disclosures
(within past 24 months, reported on Feb 27, 2026)
Honorarium/Expenses
Novo Nordisk (ended)
Dajana Vuckovic, PhD Concordia University
Covering the topic area of Metabolic Analysis
Dr. Dajana Vuckovic is Professor and Concordia University Research Chair in Clinical Metabolomics and Biomarkers and the Director of Centre for the Biological Applications of Mass Spectrometry at Concordia University. Her research program focuses on the development of novel mass spectrometry and microextraction methods to accurately measure challenging low-abundance and unstable metabolites and improve metabolite coverage and data quality in clinical metabolomics and lipidomics. Dr. Vuckovic is the recipient of the 2023 Fred Beamish Award from the Canadian Society for Chemistry and the 2024 Metabolomics Society medal. She serves on the editorial boards of Bioanalysis and Analytical and Bioanalytical Chemistry and currently co-leads the Best Practices Working Group of Metabolomics Quality Assurance and Quality Control Consortium. She has co-organized numerous scientific symposia at leading national and international conferences and has co-chaired Metabolomics 2023 conference held in Niagara Falls, Canada.
Relevant Financial Disclosures
(within past 24 months, reported on Mar 12, 2026)
No relevant financial relationship(s) to disclose.
Thomas Horvath, PhD Baylor College of Medicine / Texas Children's Hospital
Covering the topic area of Microbial Analysis
I am an Assistant Professor in possession of nearly 23 years of academic and FDA/EMEA-regulated pharmaceutical-industry research experience in the field of bioanalytical chemistry. Over the course of my career, I have acquired considerable skill in the development and validation of high-throughput LC-MS/MS-based bioanalytical methods to measure exogenous small-molecule therapeutics (e.g., pharmaceuticals and peptides) or endogenous bio-molecules (e.g., metabolites and lipids) in an assortment of biological matrices and homogenized tissues. I have developed methods which have been implemented in host of projects, including: i) PK/PD assessments of therapeutic small-molecules or enzyme-based drugs; ii) assess the effectiveness or bioequivalence of novel, off-patent formulations; iii) investigate the mechanism of action of new therapeutic compounds; and iv) determine alterations in metabolic pathways based on disease state or therapeutic intervention. My publication record spans a diverse subset of life science research that includes nutritional biochemistry, mosquito metabolism using carbon-13 isotope tracing, and microbiological applications including methods to interrogate the mammalian gut-brain-axis, and pharmaceutical discovery and development. My current research focuses on dissecting microbial derived compounds and their impact on host physiology.
Relevant Financial Disclosures
(within past 24 months, reported on Mar 24, 2026)
No relevant financial relationship(s) to disclose.
Deborah French Ph.D., DABCC (CC, TC), FADLM is a Director of Chemistry and the Director of Mass Spectrometry at the University of California San Francisco Health Clinical Laboratories. Her work currently focuses on the development and validation of LC-MS/MS assays for small molecules, specifically therapeutic drug monitoring, steroid hormones and toxicology. Deborah received her Ph.D. in biochemistry from the University of Strathclyde in Glasgow, Scotland and then completed a postdoctoral fellowship at St. Jude Children’s Research Hospital in Memphis, TN. She subsequently completed a ComACC Clinical Chemistry postdoctoral fellowship under the direction of Dr Alan Wu at the University of California San Francisco and is now board certified in Clinical Chemistry and Toxicological Chemistry by the American Board of Clinical Chemistry.
Relevant Financial Disclosures
(within past 24 months, reported on Feb 27, 2026)
Consultant Fees
ARK Diagnostics, Roche Diagnostics (ended)
Matthew Crawford Labcorp
Covering the topic area of Small Molecule
Matthew Crawford is a Scientist II working in research and development at Labcorp in Burlington, North Carolina. He received his B.S. in Biochemistry from California State University, Northridge and is currently working towards his Ph.D. in Analytical Chemistry from University of Texas at Arlington under the instruction of Professor Kevin Schug. At Labcorp, his focus is high-throughput method development and validation for small molecule biomarkers using LC-MS/MS and GC-MS. He’s been on the MSACL steering committee for 2024 and 2025 conferences where he’s head of the small molecule scientific committee.
Relevant Financial Disclosures
(within past 24 months, reported on Apr 23, 2026)
Honorarium/Expenses
MSACL
Stock/Bonds
Labcorp
Salary
Labcorp
Ron Heeren, PhD Maastricht University
Covering the topic area of Spatialomics
Maastricht University Professor Ron Heeren (1965) is a pioneer in the field of imaging mass spectrometry. During his career, he and his team have developed new physical measurement methods to map the distribution of molecules on complex surfaces. In all phases of his scientific career, he has actively contributed to the valorisation of the methods and techniques he has developed in a highly interdisciplinary setting. Instrumentation physics was and is the common thread through his development into the socially committed scientist he is today. Trained as a technical physicist, with an outstanding track record in innovative physical-chemical research, he is now active in an interdisciplinary biomedical setting. He heads the Maastricht MultiModal Molecular Imaging Institute (M4I) in which he uses the techniques he has developed for precision medicine and improved patient care. He has also actively given his research more (market) value through the establishment and participation in three companies. Various of the patents obtained by him have been taken over and / or licensed by various major private parties active in the scientific instrumentation market.
Relevant Financial Disclosures
(within past 24 months, reported on Mar 06, 2026)
No relevant financial relationship(s) to disclose.
Scientific Committee
Magdalena Bolek, PhD NSW Health Pathology
Covering the topic area of (Glyco)Proteomics
Magda is a Medical Laboratory Scientist at the Royal North Shore Hospital. She gained experience in Biomedical Research working as Postdoctoral Research Scientist in the higher education sector. Strong analytical, problem-solving and project management skills. Experienced in LC/MS/MS operation and method development, clinical and biomedical research, with good knowledge of research ethics, quality control and quality system regulations for clinical laboratory and clinical laboratory standards.
Relevant Financial Disclosures
(within past 24 months, reported on Jun 29, 2025)
No relevant financial relationship(s) to disclose.
Ruben Y. Luo, PhD, DABCC Stanford University
Covering the topic area of (Glyco)Proteomics
Ruben Y. Luo, PhD, DABCC, FADLM is an Assistant Professor of Pathology at Stanford University and an Associate Director of Clinical Chemistry Laboratory at Stanford Health Care. He received PhD in chemistry from Stanford University, worked in the clinical diagnostic industry for several years, and then completed clinical chemistry fellowship at the University of California San Francisco. Dr. Luo is dedicated to innovations in clinical diagnostics. His research focuses on (1) discovering the clinical diagnostic value of molecular characteristics of protein biomarkers, and (2) applying top-down mass spectrometry and label-free optical sensing immunoassays to characterization and accurate measurement of biomarkers. He has been an active member and conference speaker in the international clinical chemistry and mass spectrometry communities, e.g., Association for Diagnostics and Laboratory Medicine (ADLM; formerly American Association for Clinical Chemistry, AACC), American Society for Mass Spectrometry (ASMS), Mass Spectrometry & Advances in Clinical Lab (MSACL). His research awards include 2022 AACC George Grannis Award for Excellence in Research and Scientific Publication, 2020 American Society for Clinical Pathology (ASCP) “40 Under Forty” Honoree, etc. He currently serves as an associate editor of JMSACL and an editorial board member of Scientific Reports.
Relevant Financial Disclosures
(within past 24 months, reported on Apr 21, 2026)
Other Potential Conflicts
Thermo Fisher Scientific (San Jose, CA) / Research CollaborationGator Bio (Palo Alto, CA) / 2 Seed InstrumentsInstant Nanobiosciences (New Taipei City, Taiwan) / 1 Seed InstrumentCMP Scientific (Brooklyn, NY) / 1 Seed Instrument
Léon Reubsaet, PhD University of Oslo
Covering the topic area of (Glyco)Proteomics
Relevant Financial Disclosures
(within past 24 months, reported on Mar 05, 2026)
No relevant financial relationship(s) to disclose.
Mary Kathryn Bohn, PhD Unity Health Toronto
Covering the topic area of Data Science
Mary Kathryn Bohn is a clinical biochemist at Unity Health Toronto in Toronto, ON, Canada. Dr. Bohn completed her clinical chemistry postdoctoral fellowship at the University of Toronto in 2025. She obtained her PhD in Laboratory Medicine and Pathobiology at the University of Toronto where her research focused on improving the interpretation of biomarkers of health and disease in pediatrics and pregnancy as part of CALIPER (Canadian Laboratory Initiative of Pediatric Reference Intervals). Dr. Bohn has published over 50 peer-reviewed manuscripts and presented her work nationally and internationally. Her research has led to recognition from the Canadian Society for Clinical Chemists (CSCC), Canadian Institutes for Health Research (CIHR), and Association of Diagnostics and Laboratory Medicine (ADLM). Mary Kathryn is an active member of the clinical chemistry community with special interest in data analytics, harmonization, and emerging diagnostics in immunology.
Relevant Financial Disclosures
(within past 24 months, reported on Jan 22, 2026)
No relevant financial relationship(s) to disclose.
Amir Karin, PhD, FCACB Vancouver General Hospital
Covering the topic area of Data Science
Relevant Financial Disclosures
(within past 24 months, reported on Apr 17, 2026)
Not yet reported.
Ilaria Belluomo, PhD Imperial College London
Covering the topic area of Metabolic Analysis
Ilaria is currently a Research Fellow at Imperial College London. Her main research interest is the discovery and validation of volatile biomarkers in human breath using mass spectrometry, for the development of novel non-invasive diagnostic and monitoring techniques for neurological diseases.
Relevant Financial Disclosures
(within past 24 months, reported on Apr 22, 2026)
Not yet reported.
Michael Chen, MD MSc The University of British Columbia
Covering the topic area of Metabolic Analysis
Dr. Michael Chen is a clinical pathologist, specializing in clinical chemistry and translational mass spectrometry. He is the Department Head and Medical Director of Laboratory Medicine, Pathology and Medical Genetics at Island Health, and Provincial Discipline Lead at Provincial Health Services Authority. As a researcher, Dr Chen is the scientific director of UBC Translational Omics Lab in the Victoria General Hospital. He is also the director of Vancouver Island Biobank, and he co-chairs the BC Biobank Network. Dr. Chen’s research focuses on clinical mass spectrometry, biobanking, biomarker validation and clinical implementation.
Relevant Financial Disclosures
(within past 24 months, reported on Apr 18, 2026)
Ownership Interest
Pataigin Inc
Matthew Henderson, PhD, FCACB, FCCMG University of Ottawa
Covering the topic area of Metabolic Analysis
Matthew Henderson is a Laboratory Head and Biochemist at NSO and an Assistant Professor in the Department of Pediatrics at the University of Ottawa. He is a fellow of the Canadian Academy of Clinical Biochemistry and the Canadian College of Medical Geneticists with a subspecialty in Laboratory Biochemical Genetics. His work is focused on improving the accuracy and efficiency of newborn screening through both development and optimization of biochemical assays as well as development of data analysis approaches and tools.
Relevant Financial Disclosures
(within past 24 months, reported on Apr 07, 2026)
No relevant financial relationship(s) to disclose.
Jordan Bisanz, PhD Pennsylvania State University
Covering the topic area of Microbial Analysis
Jordan Bisanz is an Assistant Professor of Biochemistry and Molecular Biology, and the Dorothy Foehr and J. Lloyd Huck Early Career Chair in Host-Microbiome Interactions at the Pennsylvania State University and the One Health Microbiome Center. The Bisanz lab focuses on understanding how host-microbiota interactions shape health and disease. Through intertwining mechanistic research with the development of tools for meta-analysis-guided design of synthetic microbial communities, they are probing the complex bidirectional interaction networks between microbiotas and their hosts. The long-term goal of their research is to harness mechanistic understanding of the gut microbiota to develop new therapeutic targets and diagnostic tools.
Relevant Financial Disclosures
(within past 24 months, reported on Jan 23, 2026)
No relevant financial relationship(s) to disclose.
Catherine Hogan, MD, MSc, FRCPC University of British Columbia, BC Centre for Disease Control
Covering the topic area of Microbial Analysis
Dr. Catherine Hogan is a full-time medical microbiologist at the BCCDC Public Health Laboratory. She is also a clinical assistant professor in the Department of Pathology & Laboratory Medicine at UBC. Dr. Hogan holds an MDCM degree from McGill University (2011), and a master's degree in epidemiology from the London School of Hygiene and Tropical Medicine (2013), where she worked on the early epidemiology of HIV-1 transmission in Central Africa. She completed infectious diseases training (2017) at McGill University, a medical microbiology fellowship at Stanford University (2018) and a global health diagnostics fellowship at Stanford University (2021). She also serves as an associate editor for the Journal of Clinical Virology (2022-), and is an Editorial Board Member for the Journal of Clinical Microbiology (2024-). Dr. Hogan's main research area is the development and evaluation of infectious diseases diagnostics, with a focus on metabolomics.
Relevant Financial Disclosures
(within past 24 months, reported on Feb 09, 2026)
Other Potential Conflicts
Inflammatix / Consultant / Ended
Ipsita Mohanty, PhD Penn State University
Covering the topic area of Microbial Analysis
Relevant Financial Disclosures
(within past 24 months, reported on Apr 22, 2026)
Not yet reported.
Patrick Tang, MD, PhD, FRCPC St. Paul's Hospital
Covering the topic area of Microbial Analysis
Dr. Patrick Tang is a Clinical Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia and a Medical Microbiologist at St. Paul’s Hospital. After completing the MD/PhD program at UBC, he completed residency training in Medical Microbiology at the University of Toronto followed by post-doctoral training at the University of California, San Francisco. Dr. Tang’s clinical and research interests are in the application of genomics and metagenomics to infectious diseases and public health as well as the development of novel molecular diagnostics.
Relevant Financial Disclosures
(within past 24 months, reported on Jan 22, 2026)
No relevant financial relationship(s) to disclose.
Joshua Hayden, PhD, DABCC, FACB Cleveland Clinic
Covering the topic area of Practical Training
Joshua is currently the Section Head of Clinical Biochemistry at Cleveland Clinic. He earned his PhD in chemistry from Carnegie Mellon University. He conducted postdoctoral research at Massachusetts Institute of Technology before completing a two-year clinical chemistry fellowship at University of Washington and 4 years as Assistant Professor at Weill Medical College. Joshua has special expertise developing and overseeing mass spectrometry assays in the clinical laboratory.
Relevant Financial Disclosures
(within past 24 months, reported on Feb 27, 2026)
Honorarium/Expenses
Thermo (speaker)
Committee/Board/Advisory Board
BioPorto (ended)
Jacqueline Hubbard, PhD, DABCC Beth Israel Deaconess Medical Center, Harvard Medical School
Covering the topic area of Practical Training
Jacqueline Hubbard received her BS degree in Biochemistry from the University of Vermont. She then earned her MS and PhD in Biochemistry and Molecular Biology from the University of California, Riverside (UCR). Following a one year postdoc at UCR, Dr. Hubbard completed a Fellowship in Clinical Chemistry at the University of California, San Diego Health. She is board certified in Clinical Chemistry by the American Board of Clinical Chemistry. After fellowship, she took a position as an Assistant Professor in the Department of Pathology and Laboratory Medicine at the Geisel School of Medicine at Dartmouth and as the Assistant Director of Clinical Chemistry at Dartmouth-Hitchcock Medical Center. There, she focused on developing and validating drugs of abuse assays and SARS-CoV-2 serology testing. Next, she briefly served as a Lab Director for a small reference laboratory in PIttsburgh, PA. She then joined Beth Israel Deaconess Medical Center as the Co-Director of Clinical Chemistry and Director of Toxicology in 2024. She is also an Assistant Professor of Pathology for Harvard Medical School. Her research focus still includes mass spectrometry method development and toxicology test interpretation.
Relevant Financial Disclosures
(within past 24 months, reported on Mar 08, 2026)
No relevant financial relationship(s) to disclose.
Grace van der Gugten, B.Sc. Chemistry Provincial Health Services Authority, BCCDC Toxicology Lab
Covering the topic area of Practical Training
Grace discovered her love for clinical mass spectrometry when she began working at St Paul's Hospital in Vancouver in the special chemistry mass spec group with Dr. Dan Holmes in late 2010. Grace was challenged in this role but gained a wealth of knowledge and experience over her 10+ years in the SPH laboratory. She puts this experience and knowledge into use in her current role as Mass Spectrometry Lab Scientist in the Toxicology Lab at the BCCDC in Vancouver, BC. Grace loves developing streamlined, easy to use (if possible!) clinical mass spectrometry assays; teaching others and helping others succeed; and troubleshooting (especially when the problem is solved!).
Relevant Financial Disclosures
(within past 24 months, reported on Mar 05, 2026)
No relevant financial relationship(s) to disclose.
Lindsay Bazydlo, PhD University of Virginia
Covering the topic area of Small Molecule
EDUCATION:
Graduate School: University of Virginia (Chemistry), Charlottesville, VA
Clinical Chemistry and Laboratory Medicine Fellowship: University of Virginia, Charlottesville, VA
CLINICAL:
Laboratory testing in Clinical Chemistry, Toxicology, Hemostasis, and Endocrinology.
RESEARCH:
Liquid chromatography mass spectrometry assay methods.
Relevant Financial Disclosures
(within past 24 months, reported on Mar 17, 2026)
No relevant financial relationship(s) to disclose.
Caroline Le Goff, PhD CHU Liege
Covering the topic area of Small Molecule
She studied pharmacology at the University of Liège. After her graduation in 2003, she followed a specialization in Clinical Laboratory Medicine. During this period, she obtained her certification in clinical pharmacy, in RIA and in Blood Draw. Starting October 1st 2008, at 28 years old, she became a clinical Biologist (European specialist in Laboratory Medicine) at the University Hospital of Liège. In 2020, she obtained a PhD in Biomedical and Pharmaceutical Sciences. From 2024, she was promoted Professor in the University of Liege in clinical Medicine. Her main interests in clinical chemistry are, in particular: cardiac, inflammatory, oxidative stress biomarkers, mass spectrometry, endocrinology (steroids, vitamin D…) and sport biology. The subject of her PhD Thesis was “Impact of intensive strenuous exercise on the release of cardiac biomarkers”. Since 2012, she has been team leader of the LC-MS/MS clinical chemistry laboratory. She has also significantly invested in the development of lipidomics, contributing to the implementation of advanced analytical strategies for the characterization of lipid biomarkers in clinical practice. She is full member in the IFCC Committee on Clinical Applications of Cardiac Bio-markers. She is a member of various scientific societies such as the Royal Belgian Society of Laboratory Medicine (board), the European Society of Cardiology, the French Society of Cardiology, and the Belgian Bone club. Her activities have resulted in around 90 peer-reviewed scientific articles as first or last author and 100 as co-author, as well as numerous presentations at various congresses.
Relevant Financial Disclosures
(within past 24 months, reported on Apr 21, 2026)
Not yet reported.
Dennis Orton, PhD, FCACB Alberta Precision Labs University of Calgary
Covering the topic area of Small Molecule
I graduated with a PhD from Dalhousie University in Halifax, NS, Canada in 2014 where I worked on developing and applying quantitative proteomics workflows for biomarker discovery. I then completed a Clinical Biochemistry Fellowship in Calgary, AB, Canada in 2016 before moving on to work as a Clinical Biochemist in the Fraser Health region in British Columbia, Canada. During this time I gained significant experience in using R and RStudio, writing numerous shiny apps to perform QC management and to streamline LC-MS/MS data workflows. In 2019, I moved to my current position in Calgary where I head the Mass Spectrometry testing facility for Alberta Precision Laboratories. Primarily focussed on toxicology testing, I have overseen a transition towards more endocrine testing and eliminated low-throughput GC-MS workflows in favour of targeted, MRM based LC-MS analyses. My research is focused on promoting LC-MS technologies and development of tools and workflows to bring targeted proteomics methodologies to routine clinical application.
Relevant Financial Disclosures
(within past 24 months, reported on Jan 18, 2022)
Not yet reported.
Christophe Stove, PhD University of Ghent
Covering the topic area of Small Molecule
Christophe Stove graduated in 1999 as a Pharmacist at Ghent University. From 1999 to 2003 he did his PhD in the Laboratory of Experimental Cancerology in the Faculty of Medicine at Ghent University, followed by a post-doc in the Department for Molecular Biomedical Research in the Faculty of Sciences at Ghent University-VIB and -from Oct 2007 on- a Doctor-Assistant position in the Laboratory of Toxicology.
In February 2013 he became tenure-track assistant professor in the Faculty of Pharmaceutical Sciences and since October 2014 he is in charge of the Laboratory of Toxicology.
His activities include education, service (forensic toxicology and reference measurement services) and research. Research fields of special interest are alternative sampling strategies, the deployment of bio-analytical strategies for steering vitamin research and various aspects of G-protein-coupled receptors (GPCR’s).
Relevant Financial Disclosures
(within past 24 months, reported on Aug 03, 2021)
Not yet reported.
Peggi Angel, PhD MUSC Proteomics Center
Covering the topic area of Spatialomics
Peggi Angel is tenured Professor at Medical University of South Carolina Department of Pharmacology & Immunology and Co-Director of Mass Spectrometry Imaging. Dr. Angel’s work focuses on the contribution of spatial chemical biology to the external, endogenous environmental in disparities of disease risk, progression, and therapeutic resistance. She has developed multiple mass spectrometry imaging approaches to spatial biology all of which are designed for use on clinically archived human specimens of tissues, cells and fluids, and are developed working with clinicians. Notably, she is the inventor of a spatial method targeting the collagen proteome in formalin-fixed, paraffin-embedded tissues that integrates collagen proteomic maps with spatial transcriptomics and microscopy studies. Dr. Angel has over 14 years cumulative experience in 5 biotech startups including Glycopath, Inc., a company that leveraged glycosylation patterns as a prognostic or diagnostic tool; she currently serves on the board of N-Zyme Scientifics, a company that produces enzymes for targeted mass spectrometry imaging. Dr. Angel is committed to creating a collaborative mass spectrometry imaging community and serves as Past President for the Americas Region of the International Mass Spectrometry Imaging Society, as a Trustee for the International Mass Spectrometry Imaging Society, and as Secretary on the USHUPO Board of Directors. Dr. Angel is devoted to coaching and mentoring, particularly for females and minorities, serving on multiple committees to advise and mentor young scientists in entrepreneurship within multidisciplinary teams
Relevant Financial Disclosures
(within past 24 months, reported on Jul 20, 2025)
No relevant financial relationship(s) to disclose.
Sooraj Baijnath, PhD University of the Witwatersrand
Covering the topic area of Spatialomics
Relevant Financial Disclosures
(within past 24 months, reported on Mar 12, 2026)
No relevant financial relationship(s) to disclose.
Angela Kruse, PhD Ohio State University
Covering the topic area of Spatialomics
Angela Kruse is a Research Assistant Professor in the department of Cell and Developmental Biology and the Mass Spectrometry Research Center at Vanderbilt University. Her research integrates imaging mass spectrometry, proteomics, spatial transcriptomics, biochemistry, and microscopy to understand how diabetes affects the molecular environment in the pancreas, kidney, and eye. She received her Ph.D. in Plant Pathology with a focus in Biochemistry from Cornell University prior to conducting her postdoctoral studies under the guidance of Drs. Richard Caprioli and Jeff Spraggins at Vanderbilt University. She plans to spend her career applying and integrating cutting edge technologies to address important challenges in human health and the environment.
Relevant Financial Disclosures
(within past 24 months, reported on Mar 13, 2026)
No relevant financial relationship(s) to disclose.
Deborah French Ph.D., DABCC (CC, TC), FADLM is a Director of Chemistry and the Director of Mass Spectrometry at the University of California San Francisco Health Clinical Laboratories. Her work currently focuses on the development and validation of LC-MS/MS assays for small molecules, specifically therapeutic drug monitoring, steroid hormones and toxicology. Deborah received her Ph.D. in biochemistry from the University of Strathclyde in Glasgow, Scotland and then completed a postdoctoral fellowship at St. Jude Children’s Research Hospital in Memphis, TN. She subsequently completed a ComACC Clinical Chemistry postdoctoral fellowship under the direction of Dr Alan Wu at the University of California San Francisco and is now board certified in Clinical Chemistry and Toxicological Chemistry by the American Board of Clinical Chemistry.
Relevant Financial Disclosures
(within past 24 months, reported on Feb 27, 2026)
Consultant Fees
ARK Diagnostics, Roche Diagnostics (ended)
Joshua Hayden, PhD, DABCC, FACB Cleveland Clinic
Covering the topic area of Practical Training
Joshua is currently the Section Head of Clinical Biochemistry at Cleveland Clinic. He earned his PhD in chemistry from Carnegie Mellon University. He conducted postdoctoral research at Massachusetts Institute of Technology before completing a two-year clinical chemistry fellowship at University of Washington and 4 years as Assistant Professor at Weill Medical College. Joshua has special expertise developing and overseeing mass spectrometry assays in the clinical laboratory.
Relevant Financial Disclosures
(within past 24 months, reported on Feb 27, 2026)
Honorarium/Expenses
Thermo (speaker)
Committee/Board/Advisory Board
BioPorto (ended)
Jacqueline Hubbard, PhD, DABCC Beth Israel Deaconess Medical Center, Harvard Medical School
Covering the topic area of Practical Training
Jacqueline Hubbard received her BS degree in Biochemistry from the University of Vermont. She then earned her MS and PhD in Biochemistry and Molecular Biology from the University of California, Riverside (UCR). Following a one year postdoc at UCR, Dr. Hubbard completed a Fellowship in Clinical Chemistry at the University of California, San Diego Health. She is board certified in Clinical Chemistry by the American Board of Clinical Chemistry. After fellowship, she took a position as an Assistant Professor in the Department of Pathology and Laboratory Medicine at the Geisel School of Medicine at Dartmouth and as the Assistant Director of Clinical Chemistry at Dartmouth-Hitchcock Medical Center. There, she focused on developing and validating drugs of abuse assays and SARS-CoV-2 serology testing. Next, she briefly served as a Lab Director for a small reference laboratory in PIttsburgh, PA. She then joined Beth Israel Deaconess Medical Center as the Co-Director of Clinical Chemistry and Director of Toxicology in 2024. She is also an Assistant Professor of Pathology for Harvard Medical School. Her research focus still includes mass spectrometry method development and toxicology test interpretation.
Relevant Financial Disclosures
(within past 24 months, reported on Mar 08, 2026)
No relevant financial relationship(s) to disclose.
Grace van der Gugten, B.Sc. Chemistry Provincial Health Services Authority, BCCDC Toxicology Lab
Covering the topic area of Practical Training
Grace discovered her love for clinical mass spectrometry when she began working at St Paul's Hospital in Vancouver in the special chemistry mass spec group with Dr. Dan Holmes in late 2010. Grace was challenged in this role but gained a wealth of knowledge and experience over her 10+ years in the SPH laboratory. She puts this experience and knowledge into use in her current role as Mass Spectrometry Lab Scientist in the Toxicology Lab at the BCCDC in Vancouver, BC. Grace loves developing streamlined, easy to use (if possible!) clinical mass spectrometry assays; teaching others and helping others succeed; and troubleshooting (especially when the problem is solved!).
Relevant Financial Disclosures
(within past 24 months, reported on Mar 05, 2026)
No relevant financial relationship(s) to disclose.
